Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia..
- Author:
Ai-Hua WANG
1
;
Li ZHOU
;
Jian-Hua YOU
;
Li WANG
;
Jun-Min LI
;
Jiong HU
;
Zhi-Xiang SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; drug therapy; Piperazines; therapeutic use; Treatment Outcome
- From: Chinese Journal of Hematology 2010;31(1):11-15
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the safety and efficacy of nilotinib in chronic myelogenous leukemia (CML) patients with resistance or intolerance to imatinib.
METHODSThirty-five CML patients after imatinib failure or intolerance received oral administration of 400 mg nilotinib twice daily. The overall survival, hematologic and cytogenetic responses, as well as adverse events were evaluated.
RESULTSThe median duration of nilotinib therapy was 11 (1 - 23) months, with a median follow-up of 19 months. Nonhematologic adverse events were mostly of grade 1-2. The most common ones possibly related to nilotinib were increase of bilirubin (76%) and rash (46%). Grade 3-4 hematologic adverse events includes thrombocytopenia (37%), neutropenia (26%) and anemia (26%). Nilotinib was proved to be well-tolerated in this study. Grade 3-4 hematologic adverse events happened more frequently in advanced phase CML. The rate of major cytogenetic response in chronic phase (CP) CML was much higher than those in advanced CML (38.5% vs 22.2%). The median time to major cytogenetic response was 3 months. The estimated overall survival at 18 months was (93.5 +/- 1.0)%.
CONCLUSIONNilotinib is a more effective and safe treatment option for imatinib-resistant or -intolerant CML-CP patients.
